Brainstorm Cell Therapeutics (BCLI) Q2 2025 Earnings Report

575 Followers

Previous Report: Q1 2025

Next Report: Q3 2025

BCLI Q2 2025 EPS Results

Actual EPS-$0.34

Consensus EPS-$0.37

Beat/MissBeat by +$0.03

One Year Ago EPS$0.60

BCLI Q2 2025 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ2 2025

Date08/14/2025

TimeBefore Open

Conference CallThursday, August 14, 2025

BCLI Upcoming Earnings

Brainstorm Cell Therapeutics's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

Q2 2025 Earnings Call Audio

BCLI Q2 2025 Earnings Call

0:00 / 0:00

Q2 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2025 Earnings Call Summary

Q2 2025

Earnings Call Date:Aug 14, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.

Company Guidance

During the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call, the company emphasized its commitment to advancing the NurOwn platform for ALS treatment through a planned Phase IIIb trial called ENDURANCE, following FDA clearance in May. The trial's design has been agreed upon with the FDA under a Special Protocol Assessment (SPA), aiming to support a future Biologics License Application (BLA). Financially, Brainstorm reported R&D expenditures of $1.1 million for the quarter ending June 30, 2025, up from $0.9 million in 2024, and a net loss of $2.9 million compared to $2.5 million the previous year. The company is actively seeking funding to initiate the trial and regain NASDAQ compliance, following a transition to the OTCQB. Additionally, a Citizens Petition has been filed with the FDA by ALS patients and families, advocating for a de novo review of NurOwn's data, which includes promising five-year survival statistics from an expanded access program.

FDA Clearance for Phase IIIb Trial

Brainstorm Cell Therapeutics received FDA clearance to initiate a pivotal Phase IIIb trial, ENDURANCE, for NurOwn in early-stage ALS patients. This provides regulatory clarity and strengthens the trial's foundation.

Manufacturing Partnership with Minaris

Secured a partnership with Minaris Advanced Therapies to enhance U.S.-based manufacturing capabilities for the upcoming clinical trial.

Support from ALS Community

A citizens petition was filed with the FDA by ALS patients and families, requesting a de novo review of NurOwn's data, showcasing strong community support.

BCLI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2026 (Q3)	-0.18 / -	-0.19	―
Aug 14, 2026	2026 (Q2)	- / -0.35	-0.34	-2.94% (>-0.01)
May 15, 2026	2026 (Q1)	- / -0.19	-0.45	57.78% (+0.26)
Mar 31, 2026	2025 (Q4)	-0.28 / -0.19	-0.45	57.78% (+0.26)
Nov 14, 2025	2025 (Q3)	-0.37 / -0.19	-0.51	62.75% (+0.32)
Aug 14, 2025	2025 (Q2)	-0.37 / -0.34	0.6	-156.67% (-0.94)
May 16, 2025	2025 (Q1)	- / -0.45	-0.75	40.00% (+0.30)
Mar 31, 2025	2024 (Q4)	-0.97 / -0.45	-0.75	40.00% (+0.30)
Nov 14, 2024	2024 (Q3)	-0.57 / -0.51	-0.45	-13.33% (-0.06)
Aug 14, 2024	2024 (Q2)	-0.53 / 0.60	-1.95	130.77% (+2.55)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed